MX9707071A - Sistema de expresion de antigenos heterologos como proteinas de fusion. - Google Patents

Sistema de expresion de antigenos heterologos como proteinas de fusion.

Info

Publication number
MX9707071A
MX9707071A MX9707071A MX9707071A MX9707071A MX 9707071 A MX9707071 A MX 9707071A MX 9707071 A MX9707071 A MX 9707071A MX 9707071 A MX9707071 A MX 9707071A MX 9707071 A MX9707071 A MX 9707071A
Authority
MX
Mexico
Prior art keywords
expression
heterologous proteins
coli
fusion
polypeptides
Prior art date
Application number
MX9707071A
Other languages
English (en)
Inventor
Carlos Antonio Duarte Cano
Gerardo Enrique Guillen Nieto
Anabel Alvarez Acosta
Emilio Luis Carpio Munoz
Diogenes Quintana Vazquez
Carmen Elena Gomez Rodriguez
Ricardo De La Caridad Rodrigu
Consuelo Nazabal Galvez
Maria De Jesus Leal Angulo
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5459182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9707071(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of MX9707071A publication Critical patent/MX9707071A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion esta relacionada con la rama de la biotecnología y la ingeniería genética, particularmente con la expresion de proteínas heterologas en microorganismos mediante su fusion, usando la tecnología de ADN recombinante, a péptidos bacterianos; mediante la presente invencion se proporciona un procedimiento eficaz para la expresion en Escherichia coli de proteínas heterologas como polipéptidos de fusion con vistas a su obtencion con un alto grado de pureza, en cantidades comercialmente utiles, y de forma que permita su inclusion en preparados vacunales destinados al uso en humanos; para ello se emplea esencialmente una secuencia estabilizadora derivada de los primeros 47 amino ácidos del antígeno P64K de Neisseria meningitidis B:4 :P1.15; en particular, se usa un plasmidio recombinante conteniendo dicha secuencia bajo el control del promotor triptofano de E. coli y del terminador de la transcripcion del fago T4, incluyendo sitios de restriccion que permiten la clonacion en fase de fragmentos de ADN codificantes para polipéptidos de interés; el procedimiento objeto de la presente invencion es aplicable en la industria farmacéutica, para el desarrollo de sistemas de diagnostico, de preparados vacunales, y en cualquier situacion donde sea necesaria la obtencion en grandes cantidades de proteínas heterologas como polipéptidos de fusion en E. coli.
MX9707071A 1996-01-17 1997-01-17 Sistema de expresion de antigenos heterologos como proteinas de fusion. MX9707071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU1996010A CU22559A1 (es) 1996-01-17 1996-01-17 Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
PCT/CU1997/000001 WO1997026359A1 (es) 1996-01-17 1997-01-17 Sistema de expresion de antigenos heterologos como proteinas de fusion

Publications (1)

Publication Number Publication Date
MX9707071A true MX9707071A (es) 1997-11-29

Family

ID=5459182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707071A MX9707071A (es) 1996-01-17 1997-01-17 Sistema de expresion de antigenos heterologos como proteinas de fusion.

Country Status (22)

Country Link
US (2) US6146635A (es)
EP (1) EP0816506B1 (es)
JP (1) JP4071282B2 (es)
KR (1) KR100500782B1 (es)
CN (1) CN1107115C (es)
AR (1) AR005651A1 (es)
AT (1) ATE198491T1 (es)
AU (1) AU722317B2 (es)
BR (1) BR9704641B1 (es)
CA (1) CA2214840A1 (es)
CU (1) CU22559A1 (es)
CZ (1) CZ291097A3 (es)
DE (1) DE69703813T2 (es)
DK (1) DK0816506T3 (es)
EA (1) EA000307B1 (es)
ES (1) ES2157060T3 (es)
GR (1) GR3035690T3 (es)
HU (1) HUP9800730A3 (es)
IL (1) IL121614A (es)
MX (1) MX9707071A (es)
PT (1) PT816506E (es)
WO (1) WO1997026359A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
ES2299276T3 (es) 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos env del vih modificados.
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2003523721A (ja) * 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AUPQ347199A0 (en) * 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
ATE429643T1 (de) 2000-07-12 2009-05-15 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
EP1313850B1 (en) 2000-08-28 2008-08-06 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP2280074A3 (en) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
CU23245A1 (es) * 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
KR100447530B1 (ko) * 2001-08-14 2004-09-08 한국과학기술원 ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법
EP1427806A4 (en) * 2001-08-31 2006-04-26 Chiron Corp ANTIGENIC HIV-TYPE B POLYPEPTIDE-CODING POLYNUCLEOTIDES, POLYPEPTIDES, AND USES THEREOF
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CA2503346C (en) 2002-11-27 2014-03-18 Agensys, Inc. Nucleic acid and corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
AU2004210975B2 (en) 2003-02-10 2008-04-10 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
DK1629088T3 (da) 2003-05-30 2012-05-07 Agensys Inc Varianter af prostatastamcelleantigen (psca) og undersekvenser deraf
US20050040037A1 (en) * 2003-08-20 2005-02-24 Walton Scott G. Electron beam enhanced large area deposition system
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
CU23236A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
MXPA06013834A (es) 2004-05-28 2007-03-01 Agensys Inc Anticuerpos y moleculas relacionadas que enlazan a proteinas psca.
CN100518818C (zh) * 2004-11-15 2009-07-29 中国人民解放军军事医学科学院生物工程研究所 一种预防和/或治疗消化系统肿瘤的疫苗
EP1863848A4 (en) 2005-03-31 2009-09-23 Agensys Inc CORRESPONDING ANTIBODIES AND MOLECULES THAT ATTACH PROTEINS 161P2F10B
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2530159A1 (en) * 2011-06-03 2012-12-05 Sandoz Ag Transcription terminator sequences
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CU24705B1 (es) 2020-10-22 2024-06-11 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico que comprende el dominio extracelular de pd-l1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472658A4 (en) * 1989-05-19 1992-08-26 Biotechnology Res & Dev Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales

Also Published As

Publication number Publication date
EP0816506B1 (en) 2001-01-03
ES2157060T3 (es) 2001-08-01
US6146635A (en) 2000-11-14
AR005651A1 (es) 1999-07-14
PT816506E (pt) 2001-06-29
DE69703813T2 (de) 2001-08-09
IL121614A (en) 2006-10-31
CN1107115C (zh) 2003-04-30
HUP9800730A2 (hu) 1998-07-28
BR9704641B1 (pt) 2010-03-09
IL121614A0 (en) 1998-02-08
US6921809B1 (en) 2005-07-26
EP0816506A1 (en) 1998-01-07
EA000307B1 (ru) 1999-04-29
CA2214840A1 (en) 1997-07-24
EA199700244A1 (ru) 1998-02-26
ATE198491T1 (de) 2001-01-15
KR100500782B1 (ko) 2005-11-25
GR3035690T3 (en) 2001-07-31
KR19980703043A (ko) 1998-09-05
DE69703813D1 (de) 2001-02-08
AU722317B2 (en) 2000-07-27
DK0816506T3 (da) 2001-05-21
JPH11503617A (ja) 1999-03-30
CU22559A1 (es) 1999-05-03
HUP9800730A3 (en) 1999-07-28
CZ291097A3 (cs) 1998-11-11
AU1539697A (en) 1997-08-11
WO1997026359A1 (es) 1997-07-24
CN1177982A (zh) 1998-04-01
JP4071282B2 (ja) 2008-04-02
BR9704641A (pt) 1998-06-09

Similar Documents

Publication Publication Date Title
MX9707071A (es) Sistema de expresion de antigenos heterologos como proteinas de fusion.
JP6305478B2 (ja) 発現系
HUT66833A (en) Expression of recombinant proteins in attenuated bacteria
MX9702714A (es) Produccion de peptidos en plantas como fusiones de proteinas con revestimiento viral.
PL325373A1 (en) Compounds and methods useful in tuberculosos immunotherapy and diagnostics
AU1189195A (en) Recombinant protein production in bovine adenovirus expression vector system
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
AU7235794A (en) Vaccine compositions
NO902251L (no) Fremstilling av gonoreiske p1-proteiner og vaksiner.
Jackson et al. Analysis of the membrane‐binding domain of penicillin‐binding protein 5 of Escherichia coli
Portier Physical localisation and direction of transcription of the structural gene for Escherichia coli ribosomal protein S15
AU1541595A (en) Expression of heterologous proteins in attenuated bacteria using the htra-promoters
ATE167897T1 (de) Expressionsvektoren und verfahren zur herstellung intrazellularer proteine
WO2001046412A3 (de) Interaktionsprotein für stat transkriptionsfaktor

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees